Improving HIV prevention and care for adolescents and young adults in Uganda
Implementation Science to Understand and Design Stakeholder Informed Innovative Interventions to Improve Adolescent and Youth HIV Prevention and Care Continuums in Rural and Urban Uganda
This project offers new ways to deliver long-acting HIV prevention and stronger treatment support for adolescents and young adults (ages 15–24) in Uganda.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mu-Jhu Care NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project ID | NIH-11395127 on NIH RePORTER |
What this research studies
If you join, you may be offered long-acting injectable HIV prevention (cabotegravir) or support services tailored to youth to help you start and stay on prevention or treatment. The project uses new risk screening methods and community-friendly delivery options so services can be provided at clinics or in community settings rather than only at hospitals. For young people living with HIV, a multi-component package called SEARCH-Youth provides life-stage based assessment and support to help reach and keep viral suppression. The study runs in both rural and urban areas of Uganda and combines practical delivery tests with measures of health outcomes to see what works in real-world care.
Who could benefit from this research
Good fit: Ideal candidates are adolescents and young adults aged 15–24 who are at high risk for HIV or who are living with HIV and receive care at participating clinics or community sites in Uganda.
Not a fit: People younger than 15, older than 24, or those who cannot access the participating sites in Uganda are unlikely to be eligible or directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could make it easier for young people in Uganda to avoid HIV with long-acting prevention and to achieve and maintain viral suppression if they have HIV.
How similar studies have performed: Large clinical trials have shown long-acting cabotegravir can prevent HIV, and youth-focused delivery models show promise, but combining these approaches in routine Ugandan settings is relatively new.
Where this research is happening
Kampala, Uganda
- Mu-Jhu Care — Kampala, Uganda (Active)
Researchers
- Principal investigator: Musoke, Philippa — Mu-Jhu Care
- Study coordinator: Musoke, Philippa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.